Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021

Autor: Samuel K. Peasah, Elizabeth C. S. Swart, Yan Huang, Sandra L. Kane-Gill, Amy L. Seybert, Urvashi Patel, Chronis Manolis, Chester B. Good
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Drugs - Real World Outcomes, Vol 11, Iss 2, Pp 241-249 (2024)
Druh dokumentu: article
ISSN: 2199-1154
2198-9788
DOI: 10.1007/s40801-024-00416-3
Popis: Abstract Background Disease-modifying anti-rheumatic drugs (DMARDs), since their introduction in 1990, have revolutionized the management of rheumatoid arthritis. Newer DMARDs have recently been approved, influencing treatment patterns and clinical guidelines. Objective To update the current prescribing patterns of DMARDs in the pharmacotherapy of rheumatoid arthritis (RA) to include the pandemic era. Methods This was a retrospective cross-sectional multi-year study. Using Optum’s Clinformatics® Data Mart Database, we summarized trends in the prevalence of DMARD use in the USA from 2016 to 2021 by year for adult patients ≥ 18 years old with at least one medical RA claim and one pharmacy/medical claim of a DMARD medication. Trends included type of DMARD, class of DMARD (conventional (csDMARDs), biologics [tumor necrosis factor (TNFi) and Non-TNFi), and Janus kinase inhibitors (JAKs)], and triple therapy [methotrexate (MTX), hydroxychloroquine (HCQ), sulfasalazine (SUL)] used. Results The total sample from 2016 to 2021 was 670,679 commercially insured patients. The average age was 63.7 years (SD 13.6), and 76.7% were female and 70% were White. csDMARDs remain the most prescribed (ranging from 77.2 to 79.2%). Although JAKs were the least prescribed DMARD class, their proportion more than doubled from 2016 (1.5%) to 2021 (4%). MTX utilization declined from 40% in 2016 to 34% in 2021. In contrast, HCQ use increased during the pandemic era from
Databáze: Directory of Open Access Journals
Externí odkaz: